NAPA, Calif., March 6 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that the Company has brought on two Veteran Sales and Marketing Executives, and the appointment of a Vice President of Communications.
Michael Campagnoli joined the Company in December and has been appointed Executive Director. In addition, Phillip Rose has been retained as Consultant for Sales and Marketing. Both men will be involved in the commercialization of Senetek's proprietary technology, and will oversee product marketing collaborations for the Company.
Michael Campagnoli began his pharmaceutical career at Pfizer Corporation before joining GlaxoSmithKline as Marketing Manager. At PediaMed Pharmaceuticals, Mr. Campagnoli was National Sales and Marketing Manager and later assumed the position of Director of Business Development. Most recently, Mr. Campagnoli was the Executive Director of Sales and Business Development for PARI Pharma, a Virginia-based specialty pharmaceutical company. He is a graduate of Western Maryland College and holds a Masters from the University of Maryland.
Mr. Campagnoli stated, "I am pleased to be a part of the Senetek team at this important time when we are poised to accelerate the commercialization of the Company's technology."
Phillip Rose has thirty years of experience in domestic and international sales, marketing, commercial development, licensing, regulatory affairs and general executive management of large public and multi-national pharmaceutical research, development and sales and marketing organizations. For nine years, Mr. Rose was Vice President of Corporate Sales for Glaxo Pharmaceuticals, Inc. In 1997 he became Vice President and General Manager of North American Operations for ICN Pharmaceuticals, Inc. (now Valeant Pharmaceuticals). He then went on to become President and CEO of Obagi Medical Products, a specialty pharmaceutical company focused in aesthetic medicine, selling products and services directly through dermatologists and plastic surgeons, as well as a network of wholly owned subsidiaries and distributors, internationally. He is a graduate of Union University, Albany College of Pharmacy, and is a licensed pharmacist.
Regarding his new assignment with Senetek, Mr. Rose commented, "I am looking forward to bringing my skills and experience to the outstanding market opportunity that exists for Senetek's portfolio of dermatological compounds."
"The substantial experience and accomplishments brought to the Company by Michael Campagnoli and Phillip Rose will support Senetek's marketing and sales objectives," stated Frank Massino, Chairman and Chief Executive Officer of Senetek, "as we focus on successfully commercializing our rich intellectual property porfolio."
Senetek's new Vice President of Communications, Marjorie Hays, returns to the Company to administer Investor Relations and media communications programs, marketing strategy and positioning for commercial product development. Ms. Hays came to corporate communications with a background in asset management at major financial institutions including, Mitchell Hutchins Investment Advisory and Lazard Freres & Company. She is a graduate of Stony Brook University.
About Senetek PLC
Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.
For more information, visit the company's website at http://www.senetekplc.com.
This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.
|SOURCE Senetek PLC|
Copyright©2008 PR Newswire.
All rights reserved